<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41000392</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials.</ArticleTitle><Pagination><StartPage>1605877</StartPage><MedlinePgn>1605877</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1605877</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2025.1605877</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Despite advances in targeted therapies and immune checkpoint inhibitors (ICIs), the prognosis for advanced non-small cell lung cancer (NSCLC) remains poor. Bispecific antibodies (BsAbs) represent an emerging class of dual-target immunotherapies, yet their comparative efficacy and safety profiles lack comprehensive quantitative synthesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This systematic review and meta-analysis (PROSPERO CRD420251005168) adhered to PRISMA guidelines. We systematically searched PubMed, Web of Science, Scopus, and Embase through March 2025 for phase III randomized controlled trials (RCTs) comparing dual-target immunotherapies with conventional therapies in advanced NSCLC. Primary outcomes were progression-free survival (PFS) and overall survival (OS); secondary outcomes included objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). Risk of bias was assessed using Cochrane RoB 2.0. Random-effects models were used for data synthesis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Six RCTs (<i>n</i>=3,063 patients) were included. Dual-target immunotherapies significantly improved PFS (HR= 0.58, 95% CI: 0.43-0.78; <i>p</i>&lt;0.001) and ORR (RR=1.29,95%CI: 1.01-1.64; <i>p</i>=0.04) compared to conventional therapies. No significant OS (HR=0.84,95% CI: 0.68-1.05; <i>p</i>=0.13) or DCR (RR=1.09, 95% CI: 0.92-1.30; <i>p</i>=0.30) benefits were observed. Subgroup analyses stratified by mechanism showed no statistically significant differences in efficacy and safety between dual-target immunotherapies with different targets of action. Safety analyses revealed increased risks of any adverse events (RR=1.05; 95%CI: 1.02-1.09), grade&#x2265;3 AEs (RR=1.63; 95% CI: 1.37-1.94), serious AEs (RR=1.49; 95%CI:1.31-1.69) and AEs leading to treatment discontinuation (RR=2.49; 95% CI: 1.72-3.62) with dual-target immunotherapies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our findings, based on phase III RCTs, are limited by substantial heterogeneity among included studies. Dual-target immunotherapies demonstrate superior PFS and ORR in NSCLC but are associated with increased toxicity, particularly with EGFR/MET-targeted agents. While offering a promising therapeutic advance, safety optimization and biomarker-driven patient selection are critical for clinical translation. Further trials are needed to validate long-term survival benefits and refine risk-benefit profiles.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/prospero/, identifier CRD420251005168.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Zhang, Wang, Yang and Lei.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Yike</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biophysics, College of Basic Medical Sciences, Naval Medical University, Shanghai,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Haozhe</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biophysics, College of Basic Medical Sciences, Naval Medical University, Shanghai,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Xinyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biophysics, College of Basic Medical Sciences, Naval Medical University, Shanghai,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Changhai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biophysics, College of Basic Medical Sciences, Naval Medical University, Shanghai,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018033">Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018033" MajorTopicYN="Y">Antibodies, Bispecific</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NSCLC</Keyword><Keyword MajorTopicYN="N">bispecific antibodies</Keyword><Keyword MajorTopicYN="N">dual-target immunotherapies</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41000392</ArticleId><ArticleId IdType="pmc">PMC12457429</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2025.1605877</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229&#x2013;63. doi:&#xa0; 10.3322/caac.21834, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21834</ArticleId><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. (2019) 25:585&#x2013;94. doi:&#xa0; 10.1016/j.molmed.2019.04.012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.04.012</ArticleId><ArticleId IdType="pubmed">31155338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. (2020) 41:1&#x2013;24. doi:&#xa0; 10.1016/j.ccm.2019.10.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2019.10.001</ArticleId><ArticleId IdType="pubmed">32008623</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev. (2023) 116:102545. doi:&#xa0; 10.1016/j.ctrv.2023.102545, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2023.102545</ArticleId><ArticleId IdType="pubmed">37030062</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann U, Kontermann RE. Bispecific antibodies. Science. (2021) 372:916&#x2013;7. doi:&#xa0; 10.1126/science.abg1209, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg1209</ArticleId><ArticleId IdType="pubmed">34045345</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed Y, Amivantamab Y. First approval. Drugs. (2021) 81:1349&#x2013;53. doi:&#xa0; 10.1007/s40265-021-01561-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01561-7</ArticleId><ArticleId IdType="pubmed">34292533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Xu N, Li Z, Shen L, Ji K, Zhen Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol. (2023) 24:1134&#x2013;46. doi:&#xa0; 10.1016/S1470-2045(23)00411-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(23)00411-4</ArticleId><ArticleId IdType="pubmed">37797632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, et al. Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncol. (2024) 10:621&#x2013;33. doi:&#xa0; 10.1001/jamaoncol.2024.0057, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2024.0057</ArticleId><ArticleId IdType="pmc">PMC10958389</ArticleId><ArticleId IdType="pubmed">38512301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Liang XY, Wang ZS, Sun A, Cao TB, Zhang YP, et al. Efficacy of immune checkpoint inhibitors for NSCLC in patients with different age: A systematic review and meta-analysis. Asian J Surg. (2024) 47:4691&#x2013;8. doi:&#xa0; 10.1016/j.asjsur.2024.03.145, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asjsur.2024.03.145</ArticleId><ArticleId IdType="pubmed">38641539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hu J, Bu F, Zhang H, Fei K, Zhang P, et al. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. BMC Cancer. (2020) 20:707. doi:&#xa0; 10.1186/s12885-020-07206-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07206-4</ArticleId><ArticleId IdType="pmc">PMC7392646</ArticleId><ArticleId IdType="pubmed">32727409</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM, et al. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer. (2019) 135:196&#x2013;204. doi:&#xa0; 10.1016/j.lungcan.2019.07.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2019.07.010</ArticleId><ArticleId IdType="pubmed">31446995</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. (2010) 8:336&#x2013;41. doi:&#xa0; 10.1016/j.ijsu.2010.02.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2010.02.007</ArticleId><ArticleId IdType="pubmed">20171303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:l4898. doi:&#xa0; 10.1136/bmj.l4898, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Sg T. Controlling the risk of spurious findings from meta-regression. Stat Med. (2004) 23:1663&#x2013;82. doi:&#xa0; 10.1002/sim.1752, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1752</ArticleId><ArticleId IdType="pubmed">15160401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dersimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. (2007) 28:105&#x2013;14. doi:&#xa0; 10.1016/j.cct.2006.04.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2006.04.004</ArticleId><ArticleId IdType="pubmed">16807131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang W, Zhao Y, Luo Y, Yang R, Huang Y. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A randomized clinical trial. JAMA. (2024) 332:561&#x2013;70. doi:&#xa0; 10.1001/jama.2024.10613, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.10613</ArticleId><ArticleId IdType="pmc">PMC11337070</ArticleId><ArticleId IdType="pubmed">38820549</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A, Wang J, Wang Y, Lee S-H, Melosky B, Shih J-Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. (2024) 35:77&#x2013;90. doi:&#xa0; 10.1016/j.annonc.2023.10.117, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.10.117</ArticleId><ArticleId IdType="pubmed">37879444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. (2024) 391:1486&#x2013;98. doi:&#xa0; 10.1056/NEJMoa2403614, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403614</ArticleId><ArticleId IdType="pubmed">38924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. (2023) 389:2039&#x2013;51. doi:&#xa0; 10.1056/NEJMoa2306441, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2306441</ArticleId><ArticleId IdType="pubmed">37870976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho BC, Lee JS, Wu YL, Cicin I, Cobo Dols M, Ahn MJ, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, open-label, phase 3 trial. J Thorac Oncol. (2023) 18:1731&#x2013;42. doi:&#xa0; 10.1016/j.jtho.2023.08.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2023.08.018</ArticleId><ArticleId IdType="pubmed">37597750</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. (2025) 405:839&#x2013;49. doi:&#xa0; 10.1016/S0140-6736(24)02722-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)02722-3</ArticleId><ArticleId IdType="pubmed">40057343</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejadghaderi SA, Balibegloo M, Noori M, Fayyaz F, Saghazadeh A, Rezaei N, et al. Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert Rev Anticancer Ther. (2023) 23:307&#x2013;18. doi:&#xa0; 10.1080/14737140.2023.2183847, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737140.2023.2183847</ArticleId><ArticleId IdType="pubmed">36856069</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds GK, Maclean M, Scheffer Cliff ER, Teh BW, Thursky KA, Slavin MA, et al. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv. (2024) 8:3555&#x2013;9. doi:&#xa0; 10.1182/bloodadvances.2024012916, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2024012916</ArticleId><ArticleId IdType="pmc">PMC11261259</ArticleId><ArticleId IdType="pubmed">38625983</ArticleId></ArticleIdList></Reference><Reference><Citation>Billowria K, Das Gupta G, Chawla PA. Amivantamab: A new hope in targeting non-small cell lung cancer. Anticancer Agents Med Chem. (2023) 23:124&#x2013;41. doi:&#xa0; 10.2174/1871520622666220523145609, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871520622666220523145609</ArticleId><ArticleId IdType="pubmed">35616682</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla AA, Jatwani K, Singh R, Reddy A, Jaiyesimi I, Desai A, et al. Bispecific antibodies in lung cancer: A state-of-the-art review. Pharm (Basel). (2023) 16. doi:&#xa0; 10.3390/ph16101461, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16101461</ArticleId><ArticleId IdType="pmc">PMC10609957</ArticleId><ArticleId IdType="pubmed">37895932</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q, Jiao P. Anti-PD-L1-based bispecific antibodies targeting co-inhibitory and co-stimulatory molecules for cancer immunotherapy. Molecules. (2024) 29. doi:&#xa0; 10.3390/molecules29020454, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules29020454</ArticleId><ArticleId IdType="pmc">PMC10819708</ArticleId><ArticleId IdType="pubmed">38257366</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. (2024) 21:539&#x2013;60. doi:&#xa0; 10.1038/s41571-024-00905-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-024-00905-y</ArticleId><ArticleId IdType="pubmed">38822215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. (2023) 20:181&#x2013;95. doi:&#xa0; 10.20892/j.issn.2095-3941.2023.0002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2023.0002</ArticleId><ArticleId IdType="pmc">PMC10038071</ArticleId><ArticleId IdType="pubmed">36971124</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SR, Breadner D. Unveiling the synergistic potential: bispecific antibodies in conjunction with chemotherapy for advanced non-small-cell lung cancer treatment. Curr Oncol. (2025) 32. doi:&#xa0; 10.3390/curroncol32040206, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol32040206</ArticleId><ArticleId IdType="pmc">PMC12025875</ArticleId><ArticleId IdType="pubmed">40277763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Zhao H, Yang W, Zhang L. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. (2025) 22:592&#x2013;616. doi:&#xa0; 10.1038/s41571-025-01035-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-025-01035-9</ArticleId><ArticleId IdType="pubmed">40528044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao A, Zhu J, Niu T. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. (2024) 15:1348955. doi:&#xa0; 10.3389/fimmu.2024.1348955, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1348955</ArticleId><ArticleId IdType="pmc">PMC10933024</ArticleId><ArticleId IdType="pubmed">38482019</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayly-Mccredie E, Treisman M, Fiorenza S. Safety and efficacy of bispecific antibodies in adults with large B-cell lymphomas: A systematic review of clinical trial data. Int J Mol Sci. (2024) 25. doi:&#xa0; 10.3390/ijms25179736, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25179736</ArticleId><ArticleId IdType="pmc">PMC11396745</ArticleId><ArticleId IdType="pubmed">39273684</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Xi R, Mao D, Zhao X, Wu T. Efficacy and safety of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia: A systemic review and meta-analysis. Clin Lymphoma Myeloma Leuk. (2023) 23:e139&#x2013;e49. doi:&#xa0; 10.1016/j.clml.2022.12.009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2022.12.009</ArticleId><ArticleId IdType="pubmed">36593170</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds G, Scheffer Cliff ER, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. (2023) 7:5898&#x2013;903. doi:&#xa0; 10.1182/bloodadvances.2023010539, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2023010539</ArticleId><ArticleId IdType="pmc">PMC10558589</ArticleId><ArticleId IdType="pubmed">37467036</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Zhao D, Jiao Y, Dong W, Wang Z, Yan X, et al. Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis. Front Immunol. (2025) 16:1565407. doi:&#xa0; 10.3389/fimmu.2025.1565407, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2025.1565407</ArticleId><ArticleId IdType="pmc">PMC12061972</ArticleId><ArticleId IdType="pubmed">40352937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon S. Ivonescimab: first approval. Drugs. (2024) 84:1135&#x2013;42. doi:&#xa0; 10.1007/s40265-024-02073-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-024-02073-w</ArticleId><ArticleId IdType="pubmed">39073550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. (2021) 296:100641. doi:&#xa0; 10.1016/j.jbc.2021.100641, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100641</ArticleId><ArticleId IdType="pmc">PMC8113745</ArticleId><ArticleId IdType="pubmed">33839159</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors. Oncologist. (2023) 28:258&#x2013;67. doi:&#xa0; 10.1093/oncolo/oyac253, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oncolo/oyac253</ArticleId><ArticleId IdType="pmc">PMC10020814</ArticleId><ArticleId IdType="pubmed">36571770</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. (2024) 42:3593&#x2013;605. doi:&#xa0; 10.1200/JCO.24.01001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.24.01001</ArticleId><ArticleId IdType="pmc">PMC11469630</ArticleId><ArticleId IdType="pubmed">38857463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. (2024) 116:315&#x2013;27. doi:&#xa0; 10.1002/cpt.3308, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.3308</ArticleId><ArticleId IdType="pubmed">38825990</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of Malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. (2020) 52:102625. doi:&#xa0; 10.1016/j.ebiom.2019.102625, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.102625</ArticleId><ArticleId IdType="pmc">PMC6992935</ArticleId><ArticleId IdType="pubmed">31981978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins JJ, Vugmeyster Y, Dussault I, Girard P, Khandelwal A. Population pharmacokinetic analysis of bintrafusp alfa in different cancer types. Adv Ther. (2019) 36:2414&#x2013;33. doi:&#xa0; 10.1007/s12325-019-01018-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-019-01018-0</ArticleId><ArticleId IdType="pubmed">31278692</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchini C, Veronese N, Nottegar A, Shin JI, Gentile G, Granziol U, et al. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat. (2021) 20:185&#x2013;95. doi:&#xa0; 10.1002/pst.2068, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.2068</ArticleId><ArticleId IdType="pubmed">32935459</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. (2019) 10:ED000142. doi:&#xa0; 10.1002/14651858.ED000142, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.ED000142</ArticleId><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M, Higgins JP. Meta-analysis and subgroups. Prev Sci. (2013) 14:134&#x2013;43. doi:&#xa0; 10.1007/s11121-013-0377-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11121-013-0377-7</ArticleId><ArticleId IdType="pubmed">23479191</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. (2025) 392:566&#x2013;76. doi:&#xa0; 10.1056/NEJMoa2405008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2405008</ArticleId><ArticleId IdType="pmc">PMC11878197</ArticleId><ArticleId IdType="pubmed">39908431</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterlin P, Saada-Bouzid E, Moskovitz M, Pigneux A, Yuda J, Sinnollareddy M, et al. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. Expert Rev Anticancer Ther. (2024) 24:893&#x2013;904. doi:&#xa0; 10.1080/14737140.2024.2373888, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737140.2024.2373888</ArticleId><ArticleId IdType="pubmed">38946484</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectabl e stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. (2024) 42:1258&#x2013;67 e2. doi:&#xa0; 10.1016/j.ccell.2024.05.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.05.024</ArticleId><ArticleId IdType="pubmed">38906157</ArticleId></ArticleIdList></Reference><Reference><Citation>Frentzas S, Mislang ARA, Lemech C, Nagrial A, Underhill C, Wang W, et al. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer. (2024) 12. doi:&#xa0; 10.1136/jitc-2023-008037, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2023-008037</ArticleId><ArticleId IdType="pmc">PMC11033648</ArticleId><ArticleId IdType="pubmed">38642937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, et al. A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. Br J Cancer. (2024) 130:450&#x2013;6. doi:&#xa0; 10.1038/s41416-023-02519-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-023-02519-0</ArticleId><ArticleId IdType="pmc">PMC10844309</ArticleId><ArticleId IdType="pubmed">38110665</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong A, Li W, Li X, Fan Y, Ma Z, Fang J, et al. Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. Eur J Cancer. (2023) 190:112936. doi:&#xa0; 10.1016/j.ejca.2023.05.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2023.05.024</ArticleId><ArticleId IdType="pubmed">37393762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, et al. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectab le locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. (2025) 18:61. doi:&#xa0; 10.1186/s13045-025-01705-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-025-01705-2</ArticleId><ArticleId IdType="pmc">PMC12142944</ArticleId><ArticleId IdType="pubmed">40481574</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>